These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17561399)

  • 21. Regulation of phosphoinositide 3-kinase expression in health and disease.
    Kok K; Geering B; Vanhaesebroeck B
    Trends Biochem Sci; 2009 Mar; 34(3):115-27. PubMed ID: 19299143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of PI3K and MEK: it is all about combinations and biomarkers.
    Rexer BN; Ghosh R; Arteaga CL
    Clin Cancer Res; 2009 Jul; 15(14):4518-20. PubMed ID: 19584146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of PI3K class IA isoforms with regulatory subunit p55alpha using a scintillation proximity assay.
    Van Aller GS; Carson JD; Fernandes C; Lehr R; Sinnamon RH; Kirkpatrick RB; Tummino PJ; Luo L
    Anal Biochem; 2008 Dec; 383(2):311-5. PubMed ID: 18814837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract.
    Riener MO; Bawohl M; Clavien PA; Jochum W
    Genes Chromosomes Cancer; 2008 May; 47(5):363-7. PubMed ID: 18181165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer-associated mutations are preferentially distributed in protein kinase functional sites.
    Izarzugaza JM; Redfern OC; Orengo CA; Valencia A
    Proteins; 2009 Dec; 77(4):892-903. PubMed ID: 19626714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Class I PI3K in oncogenic cellular transformation.
    Zhao L; Vogt PK
    Oncogene; 2008 Sep; 27(41):5486-96. PubMed ID: 18794883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Role of phosphatidylinositol-3-kinase in the development of cancer].
    Shpakov AO
    Vopr Onkol; 2002; 48(6):644-55. PubMed ID: 12530257
    [No Abstract]   [Full Text] [Related]  

  • 28. Phosphatidylinositol 3-kinase: the oncoprotein.
    Vogt PK; Hart JR; Gymnopoulos M; Jiang H; Kang S; Bader AG; Zhao L; Denley A
    Curr Top Microbiol Immunol; 2010; 347():79-104. PubMed ID: 20582532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutated PI 3-kinases: cancer targets on a silver platter.
    Kang S; Bader AG; Zhao L; Vogt PK
    Cell Cycle; 2005 Apr; 4(4):578-81. PubMed ID: 15876869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphoinositide 3-kinases and the regulation of vesicular trafficking.
    Backer JM
    Mol Cell Biol Res Commun; 2000 Apr; 3(4):193-204. PubMed ID: 10891392
    [No Abstract]   [Full Text] [Related]  

  • 31. Tumour biology. Weakening link to colorectal cancer?
    Barbier M; Attoub S; Calvez R; Laffargue M; Jarry A; Mareel M; Altruda F; Gespach C; Wu D; Lu B; Hirsch E; Wymann MP
    Nature; 2001 Oct; 413(6858):796. PubMed ID: 11677595
    [No Abstract]   [Full Text] [Related]  

  • 32. [The possible role of spiral structures in the functional activity of the regulatory and catalytic subunits of phosphatidylinositol-3-kinases].
    Shpakov AO
    Zh Evol Biokhim Fiziol; 1999; 35(2):98-105. PubMed ID: 10519197
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug-resistant phosphatidylinositol 3-kinase: guidance for the preemptive strike.
    Vogt PK
    Cancer Cell; 2008 Aug; 14(2):107-8. PubMed ID: 18691545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of somatic mutations in phosphatidylinositol 3-kinase gene in human lymphoma and acute leukaemia.
    Bousquet M; Recher C; Queleen C; Demur C; Payrastre B; Brousset P
    Br J Haematol; 2005 Nov; 131(3):411-3. PubMed ID: 16225664
    [No Abstract]   [Full Text] [Related]  

  • 35. ProKinO: an ontology for integrative analysis of protein kinases in cancer.
    Gosal G; Kochut KJ; Kannan N
    PLoS One; 2011; 6(12):e28782. PubMed ID: 22194913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On reductionism, organicism, somatic mutations and cancer.
    Coffman JA
    Bioessays; 2005 Apr; 27(4):459; author reply 460-1. PubMed ID: 15770679
    [No Abstract]   [Full Text] [Related]  

  • 37. Origins of the mutational origin of cancer.
    Edler L; Kopp-Schneider A
    Int J Epidemiol; 2005 Oct; 34(5):1168-70. PubMed ID: 16046521
    [No Abstract]   [Full Text] [Related]  

  • 38. How many mutations in a cancer?
    Tomlinson I; Sasieni P; Bodmer W
    Am J Pathol; 2002 Mar; 160(3):755-8. PubMed ID: 11891172
    [No Abstract]   [Full Text] [Related]  

  • 39. Supercharging T cell therapy with cancer mutations.
    Marchal I
    Nat Biotechnol; 2024 Mar; 42(3):379. PubMed ID: 38491282
    [No Abstract]   [Full Text] [Related]  

  • 40. PTEN and the PI3-kinase pathway in cancer.
    Chalhoub N; Baker SJ
    Annu Rev Pathol; 2009; 4():127-50. PubMed ID: 18767981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.